Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Minerva NeurosciencesZynerba PharmaceuticalsSynlogicAnixa BiosciencesCatalyst Biosciences
SymbolNASDAQ:NERVNASDAQ:ZYNENASDAQ:SYBXNASDAQ:ANIXNASDAQ:CBIO
Price Information
Current Price$2.43$4.33$3.23$4.60$5.00
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.31.61.41.5
Analysis Score3.33.43.43.53.5
Community Score2.82.72.72.52.6
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.80.80.8
Earnings & Valuation Score0.00.61.30.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$6.75$14.04$13.25$11.00$17.00
% Upside from Price Target177.78% upside224.29% upside310.22% upside139.13% upside240.00% upside
Trade Information
Market Cap$103.81 million$178.62 million$128.10 million$124.80 million$156.66 million
Beta1.492.832.21.582.07
Average Volume607,8035,035,0401,032,670598,025472,228
Sales & Book Value
Annual RevenueN/A$90,000.00$2.22 million$250,000.00$10,000.00
Price / SalesN/A1,984.6857.70499.2115,665.50
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.71 per share$3.26 per share$4.86 per share$0.35 per share$5.68 per share
Price / BookN/A1.330.6613.140.88
Profitability
Net Income$-72,180,000.00$-32,940,000.00$-51,370,000.00$-10,020,000.00$-55,180,000.00
EPS($1.85)($1.50)($1.70)($0.59)($4.60)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-2,761.83%N/AN/A
Return on Equity (ROE)-51.19%-60.20%-41.64%-153.08%-55.23%
Return on Assets (ROA)-29.75%-52.40%-34.39%-129.89%-45.82%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio6.49%6.54%16.42%7.88%6.42%
Quick Ratio6.49%6.54%16.42%7.88%6.42%
Ownership Information
Institutional Ownership Percentage66.28%25.99%39.53%7.68%63.81%
Insider Ownership Percentage12.00%11.10%17.95%23.30%4.00%
Miscellaneous
Employees112672334
Shares Outstanding42.72 million41.25 million39.66 million27.13 million31.33 million
Next Earnings Date5/3/2021 (Estimated)5/10/2021 (Estimated)5/14/2021 (Estimated)6/8/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 ...Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 ...
apnews.com - April 12 at 1:39 PM
Catalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 DegradersCatalyst Biosciences Expands its Protease Medicines Patent Portfolio of Complement Factor 3 Degraders
finance.yahoo.com - April 12 at 8:38 AM
Reflecting on Catalyst Biosciences (NASDAQ:CBIO) Share Price Returns Over The Last Three YearsReflecting on Catalyst Biosciences' (NASDAQ:CBIO) Share Price Returns Over The Last Three Years
nasdaq.com - April 10 at 12:33 PM
Catalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare ConferenceCatalyst Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 7 at 7:47 PM
Zacks: Brokerages Expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to Post -$0.79 Earnings Per ShareZacks: Brokerages Expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to Post -$0.79 Earnings Per Share
americanbankingnews.com - March 30 at 8:26 PM
Will Catalyst Biosciences (NASDAQ:CBIO) Spend Its Cash Wisely?Will Catalyst Biosciences (NASDAQ:CBIO) Spend Its Cash Wisely?
finance.yahoo.com - March 21 at 2:17 PM
CBIO Mar 2021 5.000 callCBIO Mar 2021 5.000 call
in.finance.yahoo.com - March 18 at 2:38 PM
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate UpdateCatalyst Biosciences Reports Fourth Quarter and Full-Year 2020 Operating & Financial Results and Provides a Corporate Update
finance.yahoo.com - March 4 at 9:17 AM
Catalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors ConferenceCatalyst Biosciences to Present at the 42nd Annual Raymond James Institutional Investors Conference
finance.yahoo.com - February 18 at 12:37 PM
Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public ...Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public ...
apnews.com - February 12 at 10:02 AM
Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common StockCatalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock
finance.yahoo.com - February 11 at 6:18 PM
Benzingas Top Ratings Upgrades, Downgrades For February 10, 2021Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021
finance.yahoo.com - February 10 at 2:40 PM
CBIO Jun 2021 10.000 putCBIO Jun 2021 10.000 put
au.finance.yahoo.com - February 8 at 7:58 PM
CBIO Mar 2021 7.500 callCBIO Mar 2021 7.500 call
au.finance.yahoo.com - February 8 at 7:58 PM
Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD CongressCatalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
finance.yahoo.com - February 3 at 12:27 PM
Catalyst Biosciences Announces Closing of Public Offering of Common Stock | MorningstarCatalyst Biosciences Announces Closing of Public Offering of Common Stock | Morningstar
morningstar.com - January 29 at 7:37 PM
Catalyst Biosciences Prices 8.7M Share Offering AT $5.75/ShareCatalyst Biosciences Prices 8.7M Share Offering AT $5.75/Share
benzinga.com - January 28 at 1:00 PM
If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Shares Five Years Ago You Would Be Down 81%If You Had Bought Catalyst Biosciences' (NASDAQ:CBIO) Shares Five Years Ago You Would Be Down 81%
finance.yahoo.com - January 20 at 10:17 AM
Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual CongressCatalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
finance.yahoo.com - January 20 at 10:17 AM
Catalyst Biosciences Participating in a Fireside Chat with LifeSci CapitalCatalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
finance.yahoo.com - January 15 at 12:47 PM
VICOR CORP. Registered Shares D (VCV.SG)VICOR CORP. Registered Shares D (VCV.SG)
sg.finance.yahoo.com - January 1 at 1:15 AM
CBIO Jan 2021 7.500 callCBIO Jan 2021 7.500 call
au.finance.yahoo.com - December 26 at 11:52 PM
Catalyst Biosciences (CBIO) Gets a Buy Rating from LifeSci CapitalCatalyst Biosciences (CBIO) Gets a Buy Rating from LifeSci Capital
smarteranalyst.com - December 22 at 7:36 AM
Is CBIO A Good Stock To Buy Now?Is CBIO A Good Stock To Buy Now?
finance.yahoo.com - December 15 at 11:06 PM
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American ...Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American ...
apnews.com - December 8 at 5:51 PM
DateCompanyBrokerageAction
9/11/2020Minerva NeurosciencesWilliam BlairReiterated Rating
7/2/2020Minerva NeurosciencesHC WainwrightReiterated Rating
7/1/2020Minerva NeurosciencesJMP SecuritiesReiterated Rating
6/1/2020Minerva NeurosciencesBTIG ResearchLower Price Target
5/29/2020Minerva NeurosciencesJefferies Financial GroupDowngrade
12/2/2019Minerva NeurosciencesChardan CapitalReiterated Rating
8/3/2018Minerva NeurosciencesCitigroupBoost Price Target
3/10/2021Zynerba PharmaceuticalsRoth CapitalLower Price Target
2/5/2021Zynerba PharmaceuticalsCanaccord GenuityReiterated Rating
9/14/2020Zynerba PharmaceuticalsNeedham & Company LLCReiterated Rating
7/1/2020Zynerba PharmaceuticalsCantor FitzgeraldLower Price Target
6/29/2020Zynerba PharmaceuticalsLADENBURG THALM/SH SHReiterated Rating
3/25/2021SynlogicSVB LeerinkBoost Price Target
3/24/2021SynlogicJonestradingInitiated Coverage
5/10/2020SynlogicOppenheimerReiterated Rating
11/13/2019SynlogicPiper Jaffray CompaniesReiterated Rating
8/9/2019SynlogicWedbushReiterated Rating
2/15/2021Anixa BiosciencesAegisReiterated Rating
12/30/2019Anixa BiosciencesB. RileyLower Price Target
3/4/2021Catalyst BiosciencesRaymond JamesSet Price Target
2/10/2021Catalyst BiosciencesPiper SandlerInitiated Coverage
11/5/2020Catalyst BiosciencesLifesci CapitalReiterated Rating
8/6/2020Catalyst BiosciencesCi CapitalReiterated Rating
1/4/2019Catalyst BiosciencesCIBCInitiated Coverage
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.